

**BOB Economics Research | Trade**

Trade deficit expands as exports slip

**Indraprastha Gas | Target: Rs 565 | +18% | BUY**

Expect volume recovery from FY22

**SUMMARY**
**India Economics: Trade**

India's trade deficit expanded to US\$ 10bn in Nov'20 from US\$ 8.7bn in Oct'20 led by moderation in exports and stable non-oil-non-gold imports. Stable non-oil-non-gold imports indicate normalization of domestic economic activity. Capital goods imports continue to contract, albeit at a slower pace. Recent high frequency data point to some moderation in domestic economic activity which implies imports may remain muted. We expect trade deficit in FY21 at US\$ 82bn versus US\$ 158bn in FY20 which should support INR.

[Click here for the full report.](#)

**Indraprastha Gas**

Key takeaways from our recent interaction with the Indraprastha Gas (IGL) management: (a) volume recovery to pre-Covid levels expected by Q4FY21 as CNG volumes normalise, (b) PNGRB's clarification on third-party access at OMC outlets eases concerns over margin dilution, and (c) IGL is placing renewed emphasis on operating margin expansion to make up for earnings loss from pandemic-led volume disruptions. Our earnings estimates remain unchanged as does our Sep'21 TP of Rs 565. Volume acceleration in FY22 looks plausible.

[Click here for the full report.](#)

**TOP PICKS**
**LARGE-CAP IDEAS**

Company	Rating	Target
<a href="#">Cipla</a>	Buy	900
<a href="#">GAIL</a>	Buy	155
<a href="#">Petronet LNG</a>	Buy	330
<a href="#">TCS</a>	Buy	3,180
<a href="#">Tech Mahindra</a>	Buy	1,040

**MID-CAP IDEAS**

Company	Rating	Target
<a href="#">Alkem Labs</a>	Buy	3,600
<a href="#">Greenply Industries</a>	Buy	150
<a href="#">Laurus Labs</a>	Buy	410
<a href="#">Transport Corp</a>	Buy	300
<a href="#">Mahanagar Gas</a>	Sell	750

Source: BOBCAPS Research

**DAILY MACRO INDICATORS**

Indicator	Current	2D (%)	1M (%)	12M (%)
US 10Y yield (%)	0.94	1bps	6bps	(84bps)
India 10Y yield (%)	5.92	(1bps)	4bps	(55bps)
USD/INR	73.80	(0.2)	0.4	(3.2)
Brent Crude (US\$/bbl)	48.25	1.8	28.8	(23.4)
Dow	29,884	0.2	12.8	8.1
Shanghai	3,449	(0.1)	7.0	19.8
Sensex	44,618	(0.1)	12.6	9.2
India FII (US\$ mn)	1 Dec	MTD	CYTD	FYTD
FII-D	(63.0)	(63.0)	(14,682.2)	(4,922.7)
FII-E	481.3	481.3	16,587.0	23,190.0

Source: Bank of Baroda Economics Research

**BOBCAPS Research**

research@bobcaps.in



## TRADE

03 December 2020

**Trade deficit expands as exports slip**

India's trade deficit expanded to US\$ 10bn in Nov'20 from US\$ 8.7bn in Oct'20 led by moderation in exports and stable non-oil-non-gold imports. Stable non-oil-non-gold imports indicate normalization of domestic economic activity. Capital goods imports continue to contract, albeit at a slower pace. Recent high frequency data point to some moderation in domestic economic activity which implies imports may remain muted. We expect trade deficit in FY21 at US\$ 82bn versus US\$ 158bn in FY20 which should support INR.

Sameer Narang | Sonal Badhan  
 Jahnvi

chief.economist@bankofbaroda.com

**Exports fall again:** Preliminary data shows that exports fell by 9.1% in Nov'20 after a 5.1% drop in Oct'20. Oil exports fell sharply by 63.8% in Nov'20 compared with a 52% decline in Oct'20. Non-oil export growth also eased marginally to 1.2% in Nov'20 from 1.9% in Oct'20. Within this, exports of plastics and linoleum fell the most at 23.3% compared with a 6.9% drop in Oct'20. This was followed by decline in engineering goods (8.3% versus 3.7% decline in Oct'20). Exports of drugs and pharmaceuticals also decelerated to 11.1% versus an increase of 21.9% in Oct'20. In FYTD21, exports are now down by 17.4% compared with a drop of 2.3% in FYTD20. Increase in global Covid-19 cases continues to pose risk to global growth and India's export recovery.

**Non-oil-non-gold imports improve:** India's imports contracted by 13.3% in Nov'20 compared with a decline of 11.5% in Oct'20. This was led by 43.4% decline in oil imports versus 38.5% dip in Oct'20. Sharp deceleration was also seen in gold imports as it slipped to 2.7% in Nov'20 compared with an increase of 35.9% in Oct'20. However, non-oil-non-gold imports rose by 3% in Nov'20 from 0.9% in Oct'20. Within this, import of vegetable oil and electronic goods rose the most, by 34% and 36.1% respectively. Imports of machinery and transport equipment also contracted less sharply at 13.4% and 19.6% respectively compared with 16% and 56.3% respectively in Oct'20.

**Trade deficit to expand:** India's trade deficit in Nov'20 rose to US\$ 10bn from US\$ 8.7bn in Oct'20. This is the highest monthly deficit in FYTD21 so far. However, some moderation in domestic demand is likely as seen in high frequency data such as manufacturing PMI (56.3 in Nov'20 versus 58.9 in Oct'20), diesel demand (-7% versus 7.4% in Oct'20), electricity demand (4.4% versus 5.3%) and GST collections (1.4% versus 10.2%). The outlook for exports is relatively muted due to second wave of Covid-19. We expect trade deficit to increase to US\$ 82bn in FY21 (US\$ 42.8bn in FYTD21).

**KEY HIGHLIGHTS**

- Exports fell by 9.1% in Nov'20 compared with a decline of 5.1% in Oct'20.
- Imports contract by 13.3% in Nov'20 versus a decline of 11.5% in Oct'20.
- Trade deficit rises to US\$ 10bn from US\$ 8.7bn in Oct'20.



**BUY**

TP: Rs 565 | ▲ 18%

**INDRAPRASTHA GAS**

Oil &amp; Gas

03 December 2020

## Expect volume recovery from FY22

**Key takeaways from our recent interaction with the Indraprastha Gas (IGL) management: (a) volume recovery to pre-Covid levels expected by Q4FY21 as CNG volumes normalise, (b) PNGRB's clarification on third-party access at OMC outlets eases concerns over margin dilution, and (c) IGL is placing renewed emphasis on operating margin expansion to make up for earnings loss from pandemic-led volume disruptions. Our earnings estimates remain unchanged as does our Sep'21 TP of Rs 565. Volume acceleration in FY22 looks plausible.**

Rohit Ahuja

research@bobcaps.in


**Competition never a concern – as underscored by PNGRB clarification:** IGL's well-entrenched network of 560 CNG stations (of which 320 are in OMC outlets) gives it a strong first-mover advantage. The recent PNGRB notification pertaining to third-party access clarified that OMC- and dealer-owned/operated (DODO) outlets do not classify as third party. We believe this was inevitable in light of the complexities surrounding the use of compressor stations (usually owned by the CGD operator) that would have opened up multiple disputes.

Ticker/Price	IGL IN/Rs 479
Market cap	US\$ 4.5bn
Shares o/s	700mn
3M ADV	US\$ 20.3mn
52wk high/low	Rs 534/Rs 284
Promoter/FPI/DII	45%/21%/34%

Source: NSE

**Rising dealer commissions negate need for own CGD network:** The fact that CGD players pay a steep dealer commission to OMCs (~Rs 6/scm by IGL for CNG) is being lost in the noise around competition from open access. This commission – almost at par with IGL's FY20 EBITDA – negates any need for OMCs to invest in a greenfield CGD entity, which would carry infrastructure costs (retail outlets, CNG dispensers, approvals, manpower). Also, the commission is revised every three years irrespective of margin trends for IGL. We have always believed that competition would be the least of the concerns for IGL's margins.

## STOCK PERFORMANCE



Source: NSE

**Reiterate BUY:** At 17x FY23E EPS, valuations look a bit demanding but do not factor in the margin expansion potential – in our view, this makes up for the near-term uncertainty surrounding CNG volume ramp-up.

## KEY FINANCIALS

Y/E 31 Mar	FY19A	FY20A	FY21E	FY22E	FY23E
Total revenue (Rs mn)	57,648	64,853	46,897	73,114	83,091
EBITDA (Rs mn)	12,570	15,196	13,618	20,853	22,464
Adj. net profit (Rs mn)	8,421	12,490	11,690	17,562	19,894
Adj. EPS (Rs)	12.0	17.8	16.7	25.1	28.4
Adj. EPS growth (%)	16.7	48.3	(6.4)	50.2	13.3
Adj. ROAE (%)	21.0	25.4	19.5	24.0	21.9
Adj. P/E (x)	39.8	26.9	28.7	19.1	16.9
EV/EBITDA (x)	26.2	21.8	23.6	14.9	13.5

Source: Company, BOBCAPS Research



## Disclaimer

### Recommendations and Absolute returns (%) over 12 months

**BUY** – Expected return >+15%

**ADD** – Expected return from >+5% to +15%

**REDUCE** – Expected return from -5% to +5%

**SELL** – Expected return <-5%

**Note:** Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

### Rating distribution

As of 30 November 2020, out of 87 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 44 have BUY ratings, 15 have ADD ratings, 5 are rated REDUCE and 23 are rated SELL. None of these companies have been investment banking clients in the last 12 months.

### Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

### Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

### General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2025. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have “long” or “short” positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS’s prior written consent.

#### **Other disclosures**

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS’s associates may have financial interest in the subject company. BOBCAPS’s associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.